AstraZeneca PLC (NASDAQ:AZN) saw an upside of 1.32% on Tuesday, September 21 at $59.27 after adding $0.77. The 5-day average trading volume is 8,073,296 shares of the company’s common stock. It has gained $59.42 in the past week and touched a new high 4 times within the past 5 days. An average of 5,388,689 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 11,177,189.
AZN’s 1-month performance is -1.17% or -$0.24 on its low of $55.13 reached on 09/17/21. The company’s shares have touched a 52-week low of $46.48 and high of $60.93, with the stock’s rally to the 52-week high happening on 07/12/21. YTD, AZN has achieved 17.02% or $9.16 and has reached a new high 24 times. However, the current price is down -2.72%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
AstraZeneca PLC (AZN) has a trailing price-to-earnings (P/E) ratio of 40.82, compared to 24.04 for the broader industry and 33.61 for the sector, meaning that investors are optimistic about the stock’s future prospects. The company’s PE ratio for the last five years has touched a high of 99.67 and a low of 18.94.AZN stock has a beta of 0.54. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.22 while the price-to-book (PB) in the most recent quarter is 9.80, with the price to cash flow ratio at 107.83.
AstraZeneca PLC pays an annual dividend of $1.37 per share. Its dividend yield is 2.31% and the payout ratio is 65.40%. AZN paid $0.45 a share compared with prior rate of $0.95, down -111.11% from last year’s. Dividend has been growing by 68.16% yearly.
It is projected that AstraZeneca PLC’s next ex-dividend date will be on 28-Feb. AZN is expected to distribute $0.198 as its next dividend.
AstraZeneca PLC’s quick ratio for the period ended June 29 was 1.00, with the current ratio over the same period at 1.20 meaning that AZN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.57, while the total debt to equity was 1.75. In terms of profitability, the gross margin trailing 12 months is 76.20%The trailing 12-month EBITDA margin is 27.47% while for the period ending June 29; AstraZeneca PLC’s operating margin was 19.20%. The firm’s gross profit as reported stood at $21.32 billion against revenue of $26.62 billion.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. AstraZeneca PLC’s return on assets over the past 12 months stands at 5.60%. Return on investment over the past year is 12.20%, while its return on equity (ROE) trailing 12 months is 26.00%. In comparison, the average ROE for the broader industry over the past year is 4.25.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected AZN to announce $0.43 per share in earnings in its latest quarter, but it posted $0.45, representing a 4.70% surprise. EBITDA for the quarter stood at more than $1.88 billion. AZN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 57.95 billion, with total debt at $29.89 billion
Let’s look briefly at AstraZeneca PLC (AZN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 20 September was 64.03% to suggest the stock is trending Neutral, with historical volatility in this time period at 30.15%.
The stock’s 5-day moving average is $57.25, reflecting a +5.70% or $3.19 change from its current price. AZN is currently trading +0.60% above its 20-day SMA, +15.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -2.23% and +12.07% respectively.
Stochastic %K and %D was 58.10% and 36.82% and the average true range (ATR) pointed at 1.09. The RSI (14) points at 58.91%, while the 14-day stochastic is at 89.54% with the period’s ATR at 1.01. The stock’s 9-day MACD Oscillator is pointing at 0.99 and 0.36 on the 14-day charts.
Analysts offering their rating for AZN stock have a consensus rating for the stock as Buy. Currently, 1 brokerage advisors rate AZN as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 22 have offered a “buy” rating.
What is AZN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $47.99 and a high of $103.70, with their median price target at $68.74. Looking at these predictions, the average price target given by analysts is for AstraZeneca PLC (AZN) stock is $69.54.